Navigating the new EU CTR in early phase clinical trials
56:50
Description
Related Videos
View More
View Less
Related Videos
In Early Phase
-
Play video Webinar: Strategic approaches for first-in-human (FIH) studies and early clinical development
Webinar: Strategic approaches for first-in-human (FIH) studies and early clinical development
48:56
-
Play video Webinar: KoNECT - Strategic approaches for first-in-human (FIH) studies and early clinical development
Webinar: KoNECT - Strategic approaches for first-in-human (FIH) studies and early clinical development
1:21:57
-
Play video Studies with 13C- and 14C-labelled investigational medicinal products in humans
Studies with 13C- and 14C-labelled investigational medicinal products in humans
45:28
-
Play video FDA Waivers for TQT Studies
FDA Waivers for TQT Studies
A drug's propensity to cause QT prolongation has to be carefully evaluated in the course of clinical development, and until recently, regulators have required a designated study, the thorough QT (TQT) study, to rule out a small QT effect. It has howe
1:00:02
